A biomarker study of bevacizumab and pazopanib in renal cancer

• Research type

  Research Study

• Full title

  An Open-Label Study to Investigate the Pharmacodynamics of a Repeat Dose Regimen of Bevacizumab (10 mg/kg q2w) and Escalating Repeat Doses of Pazopanib in Renal Cell Carcinoma

• IRAS ID

  6689

• Contact name

  Tim Eisen

• Sponsor organisation

  GlaxoSmithKline

• Eudract number

  2008-005053-38

• ISRCTN Number

  never started

• Research summary

  This study aims to understand how we can measure the effect of two drugs that block blood vessel growth (angiogenesis) in patients with kidney cancer. The study is in two parts, with patients receiving bevacizumab (avastin) in the first part and pazopanib in the second part. During the first part of the study, we will be performing scans [magnetic resonance imaging (MRI), Positron Emission Tomography (PET), Computer Tomography (CT)], taking blood (measuring growth factors that affect blood vessels) as well biopsies of the cancer - these are known as ??biomarkers??, and allow us to assess effect of the drug objectively. Patients will only receive 3 doses of bevacizumab. During the second part of the study, patients will receive pazopanib in escalating doses, and only blood for biomarkers will be collected. Pazopanib will be continued until such time that the patient is continuing to benefit from it, without any unacceptable side ??effects. This information will inform us which of these methods would be useful when developing drugs that block blood vessels in the future, for possible treatment of cancer.

• REC name

  East of England - Essex Research Ethics Committee

• REC reference

  09/H0301/32

• Date of REC Opinion

  8 Jun 2009

• REC opinion

  Further Information Favourable Opinion